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Abstract 
Background: Allogeneic hematopoietic stem cell transplantation (allo‑HSCT) has been established as an effective 
treatment for patients with hematological malignancies. Disease relapse remains a major cause of transplant failure. T 
cell homeostasis is critical to determine the potency of the GVT effect. Recent studies have shown the association of 
the CTLA‑4 polymorphisms with the outcome after HLA‑identical sibling allogeneic HSCT.
Methods: In this study, we focused on four CTLA‑4 polymorphisms, and analyzed the impact of donor genotypes 
and haplotypes on the conditions of 152 acute leukemia patients (ALL 83) after related HLA‑haplotype‑ mismatched 
transplantation. The four SNP genotypes (−1661, −318, CT60 and +49) were determined by TaqMan SNP genotyping 
assays.
Results: ALL recipients of donors with +49 GG showed significantly lower OS (67.7 vs. 90.3 %, P = 0.015) than those 
with GA+AA. Multivariate analyses showed that +49 GG was an independent risk factor for OS (HR: 0.306, 95 % CI 
0.111–0.842, P = 0.022) .23 ALL patients receiving mDLI showed significantly lower OS with +49 GG donor than those 
with GA+AA (30.0 vs. 83.1 %, P = 0.003). The haplotype analysis revealed only three haplotypes in the donor popula‑
tion −1661/−318/CT60/+49 i.e., ACGG, ACAA and GTGA, the frequencies were 64.1, 19.4 and 16.5 %, respectively. 
Donors with and without the ACGG/ACGG haplotype had the same effect on transplant outcomes as those with +49 
GG and +49 GA+AA.
Conclusion: In summary, the CTLA‑4 +49 GG and the haplotype ACGG/ACGG reduced the overall survival in ALL 
after allo‑HSCT from the related HLA‑haplotype‑mismatched donor, knowledge of the CTLA‑4 polymorphism and 
haplotype may provide useful information for donor selection and individual application of immunosuppressive 
agents and immunotherapy.
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Background
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) has been established as an effective treatment 
for patients with hematological malignancies. Disease 
relapse remains a major cause of transplant failure. 
Although several clinical variables including disease sta-
tus at transplant, stem cell source, graft-versus-host dis-
ease (GVHD) prophylaxis, and conditioning regimen 
contribute to the risk of relapse, the predictors of graft-
versus-tumor (GVT) effect remain largely elusive. T cell 
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Cytotoxic T lymphocyte antigen-4 (CTLA-4 or CD152) 
is a member of the immunoglobulin superfamily and is a 
T cell activation negative regulator. After the initial recog-
nition of the antigen by the T cell receptor complex, the 
primary positive co-stimulatory signal is the T cell CD28, 
which binds with CD80/CD86 on antigen-presenting 
cells. CTLA-4 is expressed in T cells after activation and 
exerts its negative regulatory effects by competing with 
CD28 for CD80/CD86 and consequently blocking down-
stream activation pathways through transendocytosis and 
degradation. CTLA-4 is highly conserved among mam-
mals, thereby indicating the importance of inhibiting pro-
liferation and inducing peripheral tolerance in T cells [4]. 
CTLA-4 is a receptor expressed on the activated T cell sur-
face and is a homolog of CD28 that is responsible for T cell 
activation. Although both CTLA-4 and CD28 bind with 
the two ligands B7.1 (CD80) and B7.2 (CD86) expressed on 
APCs, CTLA-4 binds B7 molecules with higher affinity and 
avidity than CD28. CTLA-4 gene polymorphisms correlate 
with autoimmune diseases such as systemic lupus erythe-
matosus [5, 6], type 1 diabetes mellitus [7, 8] and Graves’ 
disease [9]. Recent studies have shown the association of 
the CTLA-4 polymorphisms [−1661 (rs4553808), −318 
(rs5742909), +49 (rs231775), and CT60 (rs3087243)] with 
the outcome after HLA-identical sibling allogeneic HSCT 
[10–12]. We reported our approach to related HLA-haplo-
type-mismatched T cell-replete transplants in >1000 sub-
jects in the last 10 years [13, 14]. In the present study, we 
focused on these four CTLA-4 polymorphisms and ana-
lyzed the impact of donor genotypes and haplotypes in 152 




Between January 2010 and December 2012, a total of 
152 consecutive AL patients who underwent allo-HSCT 
at the Peking University Institute of Hematology and the 
survivors until day 100 of post-allo-HSCT were included 
in this study. All patients received related HLA-haplo-
type-mismatched T-cell-replete transplants. Each sub-
ject received a graft from a family member sharing one 
HLA haplotype with the recipient but differed to a vari-
able degree for the HLA-A, B, and DR antigens of the 
unshared HLA haplotype. All patients provided informed 
consent for treatment under a protocol reviewed and 
approved by the Peking University Institute of Hematol-
ogy. The characteristics of the patients and transplanta-
tions are summarized in Table 1.
Transplant protocols
All patients received myeloablative conditioning regimens 
[15–17]. Busulfan/cyclophosphamide (BU/CY)-based 
conditioning therapy was administered (4  mg/kg/d BU 
orally for 3 days, and 1.8 g/m2/day CY i.v. for 2 days). A 
single dose of semustine (250 mg/m2) was orally adminis-
tered to all human leukocyte antigen (HLA)-mismatched 
and related patients. They were also given cytarabine (4 g/
m2/day) and anti-thymocyte globulin (2.5  mg/kg/day, 
SangStat, Lyon, France) i.v. for 2 and 4 consecutive days, 
respectively. All subjects received granulocyte colony-
stimulating factor (G-CSF)–mobilized BM and blood 
cells. Prophylaxis against GVHD involved the treatment 
with cyclosporine A (CsA) and short-term methotrexate 
(MTX) with mycophenolate mofetil. On day 9 pre-HSCT, 
CsA (2.5  mg/kg) was treated i.v., and mycophenolate 
Table 1 Patients chracteristics and outcomes
AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, SR standard 
risk, HR high-risk, MRD minimal residual disease, IFD invasive fungal disease, CMV 
cytomegalovirus
Characteristics No. of patients (%) No. of relapse (%)
Number of patients 152 34 (22.4)
Median age, years (range) 23 (2–55) 18.5 (2–55)
Sex (male/female) 85/67 19/15
Disease type
 ALL 83 (54.6) 23 (67.6)
 AML 69 (45.4) 11 (32.4)
Disease status before HSCT
 SR 117 (77.0) 29 (85.3)
 HR 35 (23.0) 5 (14.7)
MRD status before HSCT
 MRD− remission 104 (68.4) 20 (58.8)
 MRD+ remission 43 (28.3) 12 (35.3)
 Refractory disease 5 (3.3) 2 (5.9)
HLA‑haploidentical related donor (the number of mismatched locus)
 3 93 (61.2) 19 (55.9)
 2 49 (32.2) 12 (35.3)
 1 10 (6.6) 3 (8.8)
Donor‑recipient blood type
 Match 84 (55.2) 19 (55.9)
 Minor mismatch 29 (19.1) 4 (11.8)
 Major mismatch 27 (17.8) 9 (26.4)
 Minor + major 12 (7.9) 2 (5.9)
aGVHD 48 (31.6) 12 (35.3)
 >aGVHD II 8 (5.3) 2 (5.9)
cGVHD 81 (53.3) 14 (41.2)
 Extensive cGVHD 27 (17.8) 5 (14.7)
Median follow‑up time (days) 633.5 (112–1369) 385.5 (112–1369)
Death (%) 31 (20.4) 19 (55.9)
Transplantation related death 
(%)
12 (7.9)
IFD 13 (8.6) 2 (5.9)
CMV infection 117 (77.0) 25 (73.5)
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mofetil was administered orally (0.5  g/12  h) from day 
9 before the transplantation until day 30 after the trans-
plantation. At 30  day after the transplantation, 0.25  g of 
mycophenolate mofetil was administered every 12  h for 
1–2  months. On day 1, MTX (15  mg/m2) was adminis-
tered i.v. and 10 mg/m2 MTX was given on days 3, 6, and 
11 after transplantation. Immunosuppression regimens 
were discontinued for all patients who showed AL relapse 
or increased recipient chimerism while still taking immu-
nosuppressive agents.
Sample preparation and CTLA‑4 genotyping
Donor BM or PB samples from 152 allo-HSCT patients 
were obtained to investigate CTLA4 polymorphisms 
after transplantation. DNA molecules from donor BM 
and PB samples were extracted using the Qiagen Midi 
Kit and Qiagen Mini kit (Qiagen, Hilden, Germany). 
The concentration and purity of each DNA sample were 
evaluated by measuring the optical density at 260 and 
280 nm in a UV spectrometer. The four SNP genotypes of 
CTLA-4, namely, −1661 (rs4553808), −318 (rs5742909), 
CT60 (rs3087243), and +49 (rs231775), were determined 
by TaqMan SNP genotyping assays (Applied Biosys-
tems) according to manufacturer instructions. PCR was 
performed in a 10  μL reaction volume containing 5  μL 
TaqMan Universal Master Mix (Applied Biosystems, Fos-
ter City, CA, USA), 1  mmol of each primer, 1  mmol of 
each probe, and 1 mmol of genomic DNA. Thermal cycle 
conditions were 95 °C for 10 min, 40 cycles of 95 °C for 
15  s, and 60  °C for 1  min. All PCR and endpoint fluo-
rescent readings were analyzed using an ABI 7300 Real-
Time PCR System (Applied Biosystems).
Minimal residual disease (MRD) monitoring and definition
The MRD level was determined via real-time quantita-
tive PCR and four-color flow cytometry (FCM) on bone 
marrow aspirates after HSCT [18, 19]. The MRD mark-
ers included leukemia-associated immune phenotypes 
(LAIP) and leukemia-associated genes (WT1, AML1-
ETO, CBFB-MYH11, and BCR-ABL) assayed in diagnos-
tic specimens. More than 0.001 % of LAIP via four-color 
FCM or more than 10−4 of reciprocal fusion genes or 
0.6  % of WT1 gene via real-time quantitative PCR in 
BM samples was considered as abnormal. The definition 
of MRD was two consecutive abnormalities for FCM or 
leukemia-associated genes during a 15–30 days interval.
Modified donor lymphocyte infusion (mDLI)
After diagnosing the MRD and the increasing recipi-
ent chimerism [20], pre-emptive mDLI was performed 
to prevent relapse after HSCT. Post-transplantation 
immune suppression was immediately tapered and sub-
sequently discontinued in patients who were in less than 
100  days posttransplant. Patients who were in more 
than 100  days posttransplant had the immune suppres-
sion immediately discontinued. In patients without 
active GVHD, mDLI was given based on the DLI donor 
availability. Anti-leukemia chemotherapy were admin-
istered to patients 48–72  h before mDLI; this therapy 
consisted of 20 mg aclacinomycin and 150 mg/m2 cyta-
rabine (both administered for 7  days) in acute myeloid 
leukemia (AML) patients and 1 g/m2 MTX (for 1 day) in 
acute lymphoblastic leukemia (ALL) patients. For mDLI, 
G-CSF–mobilized peripheral blood stem cells were 
administered instead of the more common, unstimu-
lated, donor blood lymphocytes. After mDLI, patients 
received immunosuppressive drugs such as CsA or MTX 
to prevent GVHD. Patients who received mDLI from an 
HLA-haploidentical donor received GVHD prophylaxis 
for 4–6  weeks at the discretion of the attending physi-
cians and depending on the GVHD status of the patient 
after mDLI. The starting dose of CsA was 2.5  mg/kg/
day and was adjusted to maintain a plasma concentra-
tion of >100 ng/mL. Moreover, 10 mg MTX was admin-
istered i.v. on days 1, 4, and 8 and weekly thereafter for 
2–6  weeks [15, 16]. Chimerism and MRD status were 
monitored at 1, 2, 3, 4.5, 6, 9 and 12  months after the 
interventions, and at 6-month intervals thereafter.
Study definitions
Neutrophil engraftment had an absolute neutrophil 
count (ANC) of >0.5 × 109/L for three consecutive days. 
Platelet engraftment without transfusion had platelet 
count of >20  ×  109/L for seven consecutive days. The 
diagnosis and grading of GVHD was established based on 
published criteria [15–17]. Patients with malignancies in 
first or second complete remission (CR1 or CR2, respec-
tively) of AL were categorized as “standard risk.” Patients 
in more than the second complete remission of AL, not in 
remission, or had high-risk cytogenetics, such as t(9;22) 
and t(4;11), were classified as “high risk.” Moreover, com-
plete remission (CR) was defined as BM blasts <5  %, 
absence of blasts with Auer rods, absence of extramed-
ullary disease, ANC of >1.0  ×  109/L, platelet count of 
>100 × 109/L, and independence of red cell transfusions. 
Partial remission (PR) included all hematological crite-
ria of CR, BM blast percentages from 5 to 20  %, and a 
decrease of pretreatment BM blast percentage by a mini-
mum of 50 %. Patients who did not achieve either of the 
mentioned standards (for CR or PR) were classified as 
no remission (NR). Relapse was defined as recurrence of 
BM blasts >5 %, reappearance of blasts in the blood, or 
development of extramedullary disease infiltrates at any 
site whereas relapse rate was the probability of leukemia 
recurrence. Over survival (OS) was calculated from the 
date of transplantation until death or last observation of 
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patients’ life. Disease-free survival (DFS) was described 
as the probability of being alive and free of disease at any 
point in time. MRD targets were also regularly examined 
within 2  weeks before transplantation. The MRD status 
before HSCT was defined as abnormal if it contained 
more than 0 0.001 % of LAIP via four-color FCM, more 
than 10−4 of reciprocal fusion genes, or more than 0.6 % 
of Wilms tumor gene 1 (WT1) [18, 19, 21]. Refractory 
disease included NR and PR patients before HSCT. A 
diagnosis of proven or probable invasive fungal disease 
(IFD)was determined by the revised European Organiza-
tion for Research and Treatment of Cancer and Mycoses 
Study Group (EORTC/MSG) criteria [22], only proven 
and probable cases were included in the determination 
of the cumulative incidence of IFD. Cytomegalovirus 
(CMV) infection was defined as isolation of CMV virus 
or detection of viral proteins or nucleic acid in any body 
fluid or tissue specimen.
Statistical analysis
The reference date of 1 October 2013 was used to define 
the end of the follow-up period. The distribution of geno-
types in the cases were calculated with Hardy–Weinberg 
equilibrium test. The statuses of DFS and OS were calcu-
lated according to the Kaplan–Meier statistics. The dif-
ferences in DFS and OS between groups were calculated 
using the log-rank test. A two-sided P value of 0.05 was 
regarded as significant. The multivariate Cox regression 
analysis was applied to examine the independence of 
predictive factors. Variables considered in the multivari-
ate models were donor sex (male vs. female), donor age 
(continuous variable), HLA mismatching locus, Donor-
recipient blood type, status of disease before HSCT, 
MRD status before HSCT, IFD and CMV infection. CMV 
serological state before HSCT was not considered as 
a covariate, because only 1  % of subjects were low risk 
(recipient-, donor-) for CMV reactivity. The independ-
ence of categorical parameters was calculated using the 
χ2-test or Fisher’s exact test, whereas the distribution of 




All patients achieved neutrophil engraftment at a mean 
time of 12  day (10–25  day). Seven patients achieved 
platelet engraftment after 100  day, and one died at 
5  months before the platelet engraftment. The median 
time of platelet engraftment was 15  day (6–225  day). 
By the 1 October 2013 end point, the median follow-up 
time was 633.5 day (112–1369 day). A total of 48 patients 
(31.6 %) developed acute GVHD, and 8 (5.3 %) developed 
acute GVHD higher than the grade II. Chronic GVHD 
developed in 81 patients (53.3 %), and extensive chronic 
GVHD developed in 27 patients (17.8  %). Overall, 34 
patients (22.4  %) relapsed after transplantation (median 
172 day, 32–1076 day). A total of 31 patients (20.4 %) died 
because of relapse (n = 19) or other causes of transplan-
tation-related mortality (n = 12; infection, n = 9; cerebral 
hemorrhage, n = 1; hemorrhage of digestive tract, n = 1; 
and post-transplantation lympho-proliferative disorders, 
n = 1) (Table 1).
Frequencies of CTLA‑4 genotypes and haplotypes
The frequencies at which the four CTLA-4 SNPs were 
expressed in the 154 donors are listed in Table  2. The 
SNP −1661 allele A was blocked by the SNP −318 allele 
C. The SNP −1661, SNP −318, CT60, and +49 were 
included in one haplotype block that was constructed 
using the international HapMap database. The hap-
lotype analysis revealed only three haplotypes in the 
donor population: −1661*A/−318*C/CT60*G/+49*G 
(ACGG), −1661*A/−318*C/CT60*A/+49*A (ACAA), 
and −1661*G/−318*T/CT60*G/+49*A/(GTGA). In this 
cohort, the frequencies of the haplotype ACGG, ACAA 
and GTGA were 64.1, 19.4 and 16.5  %, respectively. All 
of the donors were distributed among the six haplotype 
combinations (Table 3).
Effect of the four CTLA‑4 SNPs on transplant outcome
The Kaplan–Meier analysis revealed that recipients of 
donors with +49 GG showed a significantly lower OS 
(71.0 vs. 85.5  %, P  =  0.038) than those with GA+AA 
(Fig.  1a). No significant effect was found on OS of SNP 
−1661 AA/GA+GG (P = 0.208), SNP −318 CC/CT+TT 
(P = 0.208), and CT60 GG/GA+AA (P = 0.169). Moreo-
ver, the recipients showed no significant difference in 
cumulative incidence of relapse (CIR) and DFS in four 
CTLA-4 SNPs.
The ALL recipients of donors with +49 GG showed 
significantly lower OS (67.7 vs. 90.3  %, P =  0.015) than 
those with +49 GA+AA (Fig. 1b). No significant differ-
ence was observed in the OS between the AML recipients 
of donors with +49 GG and with GA+AA (P  =  0.67). 
Univariate analyses showed that treatment with the +49 
GG was a risk factor for OS in ALL (HR: 0.306, 95  % 
CI 0.111–0.842, P  =  0.022) (Table  4). Cox multivariate 
analysis considered several variables including the age, 
sex, HLA mismatching locus, status of disease before 
HSCT, MRD status before HSCT, donor-recipient blood 
type,IFD,CMV infection. Multivariate analyses showed 
that the presence of +49 GG was an independent risk 
factor for OS in ALL (HR: 0.306, 95  % CI 0.111–0.842, 
P = 0.022).
A total of 34 (22.4  %) patients relapsed after related 
HLA-haplotype-mismatched transplantation, all of these 
Page 5 of 11Qin et al. J Transl Med  (2016) 14:100 
patients received modified DLI. The Kaplan–Meier anal-
ysis indicated a significantly lower OS in patients receiv-
ing mDLI with +49 GG donor than those with GA+AA 
(23.1 vs. 57.9  %, P  =  0.010) (Fig.  2a). Further analyses 
showed a significantly lower OS in ALL patients receiving 
mDLI with the +49 GG donor than those with GA+AA 
(30.0 vs. 83.1 %, P = 0.003) (Fig. 2b). No significant dif-
ference was also observed between AML patients receiv-
ing mDLI with the +49 GG donor and with GA+AA 
(P = 0.535).
Recipients of donors with +49 GG showed signifi-
cantly higher incidence of aGVHD III–IV (10.2 vs. 2.2 %, 
P = 0.031) than those with GA+AA (Fig. 3a). However, 
no significant differences in aGVHD II–IV, cGVHD, 
and extensive cGVHD were observed between recipi-
ents of donors with the +49GG and GA+AA (P = 0.927, 
P = 0.478, P = 0.956). Univariate analyses and multivari-
ate analyses did not reveal that the +49 GG was a risk 
factor for aGVHD III–IV (HR: 0.204, 95  % CI 0.041–
1.010, P =  0.051). Recipients of donors with CT60 GG 
in ALL showed significantly lower incidence of exten-
sive cGVHD (10.5 vs. 29.2 %, P = 0.034) than those with 
GA+AA (Fig.  3b), Univariate analyses and multivari-
ate analyses reveal that the CT60 GG was a risk factor 
for extensive cGVHD (HR: 3.067, 95  % CI 1.027–9.159, 
P  =  0.045). Moreover, no significant difference in 
aGVHD III–IV, aGVHD II–IV, cGVHD, and extensive 
cGVHD in the SNP −1661, SNP −318 was observed.
There were no significant association of CTLA-4 pol-
ymorphisms with risk of infection after transplanta-
tion. No significant difference was observed in the IFD 
between the donors with +49 GG and with GA+AA 
(P = 0.534). No significant difference was observed in the 
CMV infection between the donors with +49 GG and 
with GA+AA (P = 0.870).
Table 2 Allele and genotype frequencies at the CLTA-4 loci 
in 152 donors
a The distribution of genotypes was consistent with Hardy–Weinberg 
equilibrium (P > 0.05)




No of donors 152 83 69
−1661 (rs4553808)
 AA 109 (71.7) 61 (73.5) 48 (69.6)
 AG 36 (23.7) 18 (21.7) 18 (26.1)
 GG 7 (4.6) 4 (4.8) 3 (4.3)
 A allele 254 (83.6) 140 (84.3) 114 (82.6)
 G allele 50 (16.4) 26 (15.7) 24 (17.4)
 HWE Pa 0.09 0.10 0.44
−318 (rs5742909)
 CC 109 (71.7) 61 (73.5) 48 (69.6)
 TC 36 (23.7) 18 (21.7) 18 (26.1)
 TT 7 (4.6) 4 (4.8) 3 (4.3)
 C allele 254 (83.6) 140 (84.3) 114 (82.6)
 T allele 50 (16.4) 26 (15.7) 24 (17.4)
 HWE Pa 0.09 0.10 0.44
CT60 (rs3087243)
 GG 96 (63.2) 51 (61.5) 45 (65.2)
 AG 53 (34.9) 30 (36.1) 23 (33.3)
 AA 3 (1.9) 2 (2.4) 1 (1.5)
 G allele 245 (80.6) 132 (79.5) 113 (81.9)
 A allele 59 (19.4) 34 (20.5) 25 (18.1)
 HWE Pa 0.16 0.32 0.30
+49 (rs231775)
 GG 59 (38.8) 31 (37.3) 28 (40.6)
 AG 77 (50.7) 44 (53.0) 33 (47.8)
 AA 16 (10.5) 8 (9.7) 8 (11.6)
 G allele 195 (64.1) 106 (63.9) 89 (64.5)
 A allele 109 (35.9) 60 (36.1) 49 (35.5)
 HWE Pa 0.21 0.18 0.71
Table 3 Frequencies of the CTLA-4 haplotype in 152 donors
haplotype −1661 −318 CT60 +49 All 152 donors (%) Donors in ALL (%) Donors in AML (%)
A‑C‑G‑G/A‑C‑G‑G AA CC GG GG 59 (38.8) 31 (37.4) 28 (40.6)
A‑C‑G‑G/A‑C‑A‑A AA CC GA GA 47 (30.9) 28 (33.7) 19 (27.5)
A‑C‑G‑G/G‑T‑G‑A AG CT GG GA 30 (19.7) 16 (19.3) 14 (20.3)
A‑C‑A‑A/A‑C‑A‑A AA CC AA AA 3 (2.0) 2 (2.4) 1 (1.5)
A‑C‑A‑A/G‑T‑G‑A AG CT AG AA 6 (4.0) 2 (2.4) 4 (5.8)
G‑T‑G‑A/G‑T‑G‑A GG TT GG AA 7 (4.6) 4 (4.8) 3 (4.3)
A‑C‑G‑G 195 (64.1) 106 (63.9) 89 (64.5)
A‑C‑A‑A 59 (19.4) 34 (20.4) 25 (18.1)
G‑T‑G‑A 50 (16.5) 26 (15.7) 24 (17.4)
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Effect of the CTLA‑4 haplotype on transplant outcome
SNP −1661, SNP −318, CT60, and +49 were included 
in one haplotype block that was constructed using the 
international HapMap database. The haplotype analysis 
revealed only three haplotypes in the donor population, 
as follows: −1661*A/−318*C/CT60*G/+49*G (ACGG), 
−1661*A/−318*C/CT60*A/+49*A (ACAA) and 
−1661*G/−318*T/CT60*G/+49*A (GTGA). We there-
fore focused our analysis on the ACGG and ACAA hap-
lotypes and examined their association with the outcome 
after allo-HSCT. Donors with and without the ACGG/
ACGG haplotype have the same effect on transplant 
outcome as that of donors with the +49 GG and +49 
GA+AA. Donors without and with the ACAA haplotype 
have the same effect on transplant outcome as that of 
donors with the CT60 GG and CT60 GA+AA.
Discussion
In this study, we focused on the four CTLA-4 SNP pol-
ymorphisms and analyzed the impact of donor geno-
types and haplotypes on the outcome in AL patients 
after related HLA-haplotype-mismatched transplanta-
tion. Although the association of CTLA-4 SNP and the 
outcome after allo-HSCT have been previously reported 
[10–12], we are the first to report the relationship 
between CTLA-4 SNP and the transplantation outcome 
in AL patients from related HLA-haplotype-mismatched 
donor.
The human CTLA-4 gene is located on 2q33. The 
CTLA-4 gene is composed of four exons and has two 
isoforms, a full-length isoform (flCTLA-4) and a solu-
ble form (sCTLA-4) that lacks exon 3 that encodes the 
transmembrane domain. flCTLA-4 down-regulates T 
cell responses by inducing cell cycle arrest and block-
ing cytokine production [23, 24]. Many studies have 
reported increased sCTLA-4 protein levels in patients 
with autoimmune disease [25–28]. Serum sCTLA-4 has 
the potential to bind to CD80/CD86 [29, 30]; sCTLA-4 
blocks the interaction of flCTLA-4 with CD80/CD86 and 
thereby enhances T-cell activation. CT60 maps at the 3′ 
untranslated region of CTLA-4 could play a role in the 
alternative splicing by which sCTLA-4 is generated. The 
CT60 A allele has been reported to be associated with 
a higher level of the sCTLA-4 mRNA than the CT60 G 
allele [10, 31]. The SNP −318 is located at the CTLA-4 
promoter region. Previous studies showed that the −318 
C allele is correlated with a lower promoter activity and a 
lower CTLA-4 expression than those observed with the 
−318 T allele [32, 33]. The SNP −1661 is in the upstream 
promoter region of CTLA-4. Although the −1661 is less 
characterized than other SNPs in the CTLA-4 gene [34], 
it has been associated with increased risk of multiple 
sclerosis [35], type 1 diabetes mellitus [36, 37] systemic 
sclerosis [38], oral squamous cell carcinoma [39], and 
lymph node involvement in breast cancer [40]. Testing 
the recombinant proteins of the various CTLA-4 varia-
tions, or isolating T cells from the patients with benign 
versus malignant CTLA-4 SNPs to test overall CTLA-
4-mediated immunosuppression, can provide further 
evidence to test the impact of this SNP and haplotype. 
Further research should be carried out in this field in the 
future.
In our study, the CTLA-4 +49 GG and the haplotype 
ACGG/ACGG reduced the overall survival in ALL after 
allo-HSCT from the related HLA-haplotype-mismatched 
a
b
Fig. 1 The effect of +49 genotype and haplotype on OS in AL and 
ALL patients. a OS in AL patients according to +49 genotype(GG/
GA+AA) and haplotype with or without ACGG/ACGG (P = 0.038). 
b OS in ALL patients according to +49 genotype (GG/GA+AA) and 
haplotype with or without ACGG/ACGG (P = 0.015)
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donor (67.7 vs. 90.3 %, P = 0.015). The probable mecha-
nisms that ALL patients’outcomes might be influenced by 
CTLA-4 polymorphisms were as followed: The CTLA-4 
exon 1, where the +49 polymorphism is located, encodes 
the leader peptide of the protein, which is responsible 
for CTLA-4 trafficking to the endoplasmic reticulum. 
Several previous studies reported that the CTLA-4 +49 
polymorphism alters the inhibitory effect of CTLA-4 
on T-cell activation [31, 41–43]. CTLA-4 proteins con-
tribute to the suppressor function of regulatory T cells 
(Tregs), a protein that is present in Tregs and the expres-
sion of which in Tregs is dependent on Foxp3 is CTLA-4 
[44]. Mice with Tregs that lack CTLA-4 protein expres-
sion were shown recently to develop lethal autoimmunity, 
revealing that Treg expression of CTLA-4 was necessary 
for immune suppression and prevention of in vivo auto-
immunity [45, 46]. Ipilimumab, a CTLA-4 antibody, has 
been studied in melanoma. Recently, Hodi et  al. [47] 
have shown that ipilimumab improves OS in patients 
with melanoma. In patients with melanoma, the G allele 
of rs4553808 in CTLA-4 was associated with improved 
response to ipilimumab [48]. In a phase I clinical trial 
of ipilimumab after allo-HSCT, complete remission was 
achieved in two patients with Hodgkin’s lymphoma and 
partial remission in one patient with refractory man-
tle cell lymphoma, suggesting that targeting CTLA-4 is 
feasible [49]. The mechanism of why ALL patients’ out-
comes might be influenced by CTLA-4 polymorphisms 
and haplotype needs further investigated. Recently 
PD-L1, PD-L2, LAG-3, IDO1 etc. have been reported 
to correlate to immune defects [50],to study the relation 
of CTLA4, PD-L1, PD-L2, LAG-3, IDO1, etc. with the 
evolution of immune response of HSCT patients will be 
needed in the future.
Recipients of donors with +49 GG showed signifi-
cantly higher incidence of aGVHD III–IV (10.2 vs. 
2.2  %, P  =  0.031) than those with GA+AA. Recipients 
of donors with CT60 GG in ALL showed significantly 
lower incidence of extensive cGVHD (10.5 vs. 29.2  %, 
P  =  0.034) than those with GA+AA. The effective-
ness of the CTLA-4 polymorphisms and haplotype on 
GVHD after allo-HSCT needs further investigated. The 
rates of aGVHD III–IV appear lower than our previous 
report, which reported a rate of 13.4  % [14]. The prob-
able reasons were as followed: (1) the survivors until 
day 100 of post-allo-HSCT were included in this study; 
(2) the improvement in GVHD prevention and manage-
ment over the years as well as the different proportions of 
donor gender and family relationships in the two reports, 
[13, 14] with more male donors and more child-to-parent 
pairs in the current study population (data not shown). 
Before that published report, since 2009, we intentionally 
Table 4 Univariate analyses of the CTLA-4 SNP and haplotype on outcomes in ALL after HSCT
HR indicates hazard ratio, CI confidence interval, HSCT hematopoietic stem cell transplantation
#P < 0.05
−1661 AA/AG+GG −318 CC/CT+TT CT60 GG/GA+AA +49 GG/GA+AA With ACGG/ACGG Without ACAA
Relapse
 P 0.779 0.779 0.738 0.382 0.382 0.738
 HR 0.875 0.875 0.864 0.692 0.692 0.864
 95 % CI 0.344–2.223 0.344–2.223 0.366–2.041 0.303–1.580 0.303–1.580 0.366–2.041
DFS
 P 0.575 0.575 0.666 0.240 0.240 0.666
 HR 0.784 0.784 0.844 0.645 0.645 0.844
 95 % CI 0.336–1.837 0.336–1.837 0.392–1.818 0.310–1.341 0.310–1.341 0.392–1.818
OS
 P 0.373 0.373 0.101 0.022# 0.022# 0.101
 HR 0.565 0.565 0.350 0.306 0.306 0.350
 95 % CI 0.161–1.984 0.161–1.984 0.100–1.229 0.111–0.842 0.111–0.842 0.100–1.229
aGVHD III‑IV
 P 0.527 0.527 0.862 0.324 0.324 0.862
 HR 0.030 0.030 0.809 0.299 0.299 0.809
 95 % CI 0.000–1534.4 0.000–1534.4 0.073–8.917 0.027–3.294 0.027–3.294 0.073–8.917
Extensive cGVHD
 P 0.516 0.516 0.045# 0.273 0.273 0.045#
 HR 0.655 0.655 3.067 2.041 2.041 3.067
 95 % CI 0.183–2.350 0.183–2.350 1.027‑9.159 0.569–7.322 0.569–7.322 1.027–9.159
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chose young (especially offspring), male donors who were 
identified to be associated with a lower rate of aGVHD 
under our protocol.
Perez-Garcia et  al. [10] reported that the G genotype 
of CT60 confers an inferior OS and RFS in 536 HLA-
identical sibling donor, but lower incidence of aGVHD. 
They did not report the impact on cGVHD. Vannuc-
chi et  al. [51] reported no impact of +49 and CT60 on 
OS and RFS in 147 HLA-identical matched unrelated 
donor transplantation, but identified the worse outcome 
of CT60 with AA genotype on aGVHD and cGVHD. 
In an Italian cohort, Azarian et  al. [11] did not observe 
any influence of +49 or CT60 on OS, RFS, or aGVHD in 
225 HLA-identical sibling donor, but reported a worse 
outcome on cGVHD with a G genotype of CT60. Simi-
lar findings were reported in a Tunisian cohort [52]. In a 
recent study of T-depleted allogeneic transplant, the AA 
genotype of CT60 was associated with an inferior OS and 
RFS [53]. Mossallam et  al. [54] reported that Egyptian 
recipient with +49 GA/GG allele and lower DFS and OS 
a
b
Fig. 2 The effect of +49 genotype and haplotype on OS in AL and 
ALL patients after DLI. a OS after DLI in AL patients according to 
+49 genotype(GG/GA+AA) and haplotype with or without ACGG/
ACGG (P = 0.010). b OS after DLI in ALL patients according to +49 




Fig. 3 The effect of +49 and CT60 genotype and haplotype on 
GVHD in AL and ALL patients. a aGVHD III‑IV in AL patients according 
to +49 genotype(GG/GA+AA) and haplotype with or without ACGG/
ACGG (P = 0.031). b Extensive cGVHD in ALL patients according to 
CT60 genotype (GG/GA+AA) and haplotype without or with ACAA 
(P = 0.034)
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compared with AA genotype (HR: 2.17, P = 0.03, 95 % CI 
1.05–4.48, and HR: 2.54, P = 0.01, 95 % CI 1.16–5.54).
The CTLA-4 polymorphism displays frequencies that 
are dependent on ethnicity. According to the HapMap 
Project, the frequencies of the CT60 A allele are 0.460, 
0.209 and 0.181 in European, Asians, and sub-Saharan 
Africans, respectively. Moreover, the frequencies of the 
+49 A allele are 0.611, 0.637 and 0.314 in European, 
sub-Saharan Africans, and Asians, respectively. Perez–
Garcia et al. [10] reported CT60 genotypes in 536 Euro-
pean donors: GG (24.1 %), GA (47.0 %), and AA (24.1 %). 
Metaxas et  al. [55] reported CT60 genotypes in 79 DLI 
Europeans donors: GG (45.5  %), GA (32.9  %), and AA 
(21.5 %). Murase et al. [56] reported 147 Japanese donors 
with CT60 genotypes: GG (46.9 %), GA (44.9 %), and AA 
(8.2 %). In our result, 152 Chinese donors had CT60 gen-
otype: GG (63.2 %), GA (34.9 %), and AA (1.9 %). Perez–
Garcia et al. [10] reported 536 European donors with +49 
genotype, as follows: GG (11.0 %), GA (42.4 %), and AA 
(46.6 %). Murase et al. [56] reported 147 Japanese donors 
with +49 genotype: GG (37.4  %), GA (49.7  %), and AA 
(15.6 %). In our result, 152 Chinese donors had +49 gen-
otype: GG (38.8 %), GA (50.7 %),and AA (10.5 %). Some 
of the CTLA-4 polymorphisms display frequencies that 
are different from all the other ethnic groups. The exact 
effect of the CTLA-4 polymorphism on transplant out-
come should be determined in different cohorts with a 
substantially larger number of subjects.
The SNPs −1661, −318, CT60, and +49 were included 
in one haplotype block. The SNP −1661 allele A was 
blocked by the SNP −318 allele C. The haplotype analy-
sis revealed only three haplotypes in the donor popula-
tion, in this cohort, the frequencies of the haplotype 
ACGG, ACAA, and GTGA were 64.1, 19.4 and 16.5  %, 
respectively. All the donors were distributed among the 
six haplotype combinations. In our study, recipients of 
donors with the ACGG/ACGG haplotype showed a sig-
nificantly lower OS in ALL than recipients of donors 
without the ACGG/ACGG haplotype. Murase et al. [56] 
reported that the presence of the CTLA-4 CAA (−318, 
+49, CT60) haplotype reduced the risk of relapse and 
improved survival in 147 Japanese HLA- identical sibling 
donors. They reported that three CTLA-4 haplotypes, 
CTLA-4 (−318, +49, CT60) classified as CGG, CAA and 
TAG, are present in the Japanese population. Therefore, 
further investigation is required to elucidate the effect 
of the CTLA-4 haplotype on the anti-tumor activity of 
donor-derived T cells.
Our group [57] recently reported selection of the best 
donor among the related HLA-haplotype-mismatched 
T-cell replete transplants. Our data suggest that choosing 
young, male, NIMA-mismatched donors is considerable. 
Moreover, some potentially important variables such as 
DSA, CMV serological state, KIR disparity, and other 
causes may have effect on donor selection. ALL recipi-
ents of donors with +49 GG or with haplotype ACGG/
ACGG showed significantly lower OS than GA+AA or 
without ACGG/ACGG. These results hinted that a donor 
with +49 GG or with haplotype ACGG/ACGG might be 
inferior to that with GA+AA or without ACGG/ACGG. 
CTLA-4 polymorphisms and haplotype might be as a 
potential marker of best donor selection.
The Kaplan–Meier analysis showed a significant lower 
OS in ALL patients accepting mDLI +49 GG donor or 
with haplotype ACGG/ACGG than those with AG + AA 
or without ACGG/ACGG (P = 0.003). Metaxas et al. [55] 
reported that the presence of a donor CT60 AA or GA 
genotype vs. a GG genotype was an independent factor 
for remaining in the complete chimerism/remission post-
DLI (OR =  2.61 vs. 0.42, respectively, P =  0.05). These 
results provided evidence of an independent linkage 
of the CTLA-4-SNPs and haplotype with an improved 
chance of sustained CR post-DLI, CTLA-4-SNPs and 
haplotype may act as a surrogate marker for donor lym-
phocyte infusion outcome after allo-HSCT for acute 
leukemia. This means CTLA-4 genotyping might be a 
substantial diagnostic test before DLI administration.
Conclusion
In summary, some of the CTLA-4 polymorphisms dis-
play frequencies that are different among the different 
ethnic groups. In our study the CTLA-4 +49 GG and the 
haplotype (ACGG/ACGG) reduced the overall survival 
in ALL patients after allo-HSCT from related HLA-hap-
lotype-mismatched donor. Furthermore, knowledge of 
the CTLA-4 polymorphism and haplotype may provide 
useful information for donor selection and indications 
for individual application of immunosuppressive agents 
and immunotherapy. The exact effect of the CTLA-4 pol-
ymorphism and haplotype on transplant outcome should 
be determined in different cohorts with substantially 
larger number of subjects.
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